       Document 0760
 DOCN  M9490760
 TI    Epstein-Barr virus (EBV) replicative gene expression in tumour cells of
       AIDS-related non-Hodgkin's lymphoma in relation to CD4 cell number and
       antibody titres to EBV.
 DT    9411
 AU    Brousset P; Drouet E; Schlaifer D; Icart J; Payen C; Meggetto F; Marchou
       B; Massip P; Delsol G; Department of Pathology, Centre Hospitalier
       Universitaire de; Purpan, Toulouse, France.
 SO    AIDS. 1994 May;8(5):583-90. Unique Identifier : AIDSLINE MED/94338593
 AB    OBJECTIVE: To determine whether activation of Epstein-Barr virus (EBV)
       replication in tumour cells of AIDS-related non-Hodgkin's lymphoma
       (ARNHL) is correlated with CD4+ cell counts and influences antibody
       response to EBV [anti-Z Epstein-Barr replicative activator (ZEBRA),
       anti-early antigen (EA), anti-viral capsid antigen (VCA)]. DESIGN:
       Retrospective study based on immunohistochemistry and in situ
       hybridization to detect EBV replicative gene products in tissue samples
       from patients affected by ARNHL and correlation with CD4+ cell counts
       and results of EBV serology (including anti-ZEBRA activity) in sera from
       the same patients. METHODS: Seventeen out of 22 cases of ARNHL were
       selected for the presence of EBV [Epstein-Barr early region (EBER)
       RNA-positive]. Immunohistochemistry was performed with anti-ZEBRA,
       anti-EA-restricted, anti-VCA antibodies and in situ hybridization with
       BHLF1/NotI oligoprobes on tumour samples. Results were statistically
       correlated with those of CD4+ cell counts (17 out of 17) and with
       anti-EBV antibody titres (13 out of 17) assessed using standard
       immunofluorescence method and enzyme-linked immunosorbent assay
       procedure using recombinant ZEBRA protein and synthetic peptides as
       antigens. RESULTS: BZLF1 (ZEBRA) or early gene products (EA-R and
       EA-D/BHLF1/NotI) were detected in a small proportion (< 0.01-5%) of
       tumour cells in eight of these 17 cases by immunohistochemistry and in
       situ hybridization. Demonstration of replicative gene expression did not
       correlate with either low CD4+ cell counts (P > 0.05) or anti-EBV
       antibody titres (P > 0.05). Anti-ZEBRA activity was not significantly
       increased in patients affected with ARNHL, the cells of which expressed
       replicative gene products (P > 0.05). CONCLUSION: The degree of
       immunodeficiency does not clearly enhance replicative gene expression in
       tumour cells of ARNHL. EBV serology, including anti-ZEBRA activity, is
       not a reliable tool for predicting the occurrence of such
       proliferations.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS  Adult  Antibodies,
       Viral/BIOSYNTHESIS/*BLOOD  Antibody Specificity  Antigens,
       Viral/BIOSYNTHESIS/GENETICS/IMMUNOLOGY  DNA-Binding
       Proteins/BIOSYNTHESIS/GENETICS/IMMUNOLOGY  Enzyme-Linked Immunosorbent
       Assay  Female  *Gene Expression Regulation, Neoplastic  *Gene Expression
       Regulation, Viral  Herpesviridae Infections/COMPLICATIONS  Herpesvirus
       4, Human/*GENETICS/IMMUNOLOGY/PHYSIOLOGY  Human  Leukocyte Count
       Lymphoma, AIDS-Related/*MICROBIOLOGY  Male  Middle Age  Retrospective
       Studies  Support, Non-U.S. Gov't
       Trans-Activators/BIOSYNTHESIS/GENETICS/IMMUNOLOGY  Tumor Virus
       Infections/COMPLICATIONS  *T4 Lymphocytes  *Virus Activation  Virus
       Replication  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

